IMMX Immix: Enterprise Value-to-Revenue Multiple

Public company logo of Immix Biopharma Inc. (IMMX)

The EV/Revenue multiple for Immix Biopharma, Inc. (IMMX) demonstrates moderate dynamics, supported by the recruitment of leading oncologists to develop innovative drugs. The 0.00 level reflects the current value of this metric. Meanwhile, the business relies on external contractors for production and trials, while project development is funded through the gradual expenditure of existing capital and grants.

Company Value to Revenue: Immix (IMMX) for 11/23/2025 - 11/20/2026

Immix - analytical breakdowns and key metrics (IMMX)

- share price and consensus valuation forecast:
Initial company analysis:Immix Biopharma Inc. IMMX
Product sample of Immix Biopharma Inc.

To objectively analyze asset value, a manager must correlate the total enterprise value with operating income, excluding the impact of debt load. By analyzing the enterprise value-to-revenue ratio, an investor identifies business overvaluation, which is critical for Immix Biopharma, Inc. (IMMX) during the development stage of its NXC-201 CAR-T therapy, where the absence of mass sales may create a dangerous gap between capitalization and actual cash flows.

Competitor analysis for Immix Biopharma, Inc.

IBRX (immunitybio.com) - Company Value to Revenue Ratio|Immunocore Corp (IMCR) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Janux Pharma (JANX)|Company Value to Revenue RCUS|ZYME - Enterprise Value-to-Sales Ratio|Company Value to Revenue TNGX (Tango Pharma)|Enterprise Value-to-Revenue Coefficient IOVA|EV/Sales Multiple IMTX (Immatics)|Business Value to Revenue XNCR|compasstherapeutics.com - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Replimune Inc.|Lyell Immunopharma (LYEL) - Enterprise Value-to-Revenue Ratio|Innate Pharma S.A. - Business Value to Revenue|PYXS (Pyxis) - EV/Sales Multiple|EV/Sales Multiple cgen.com|Enterprise Value-to-Revenue Ratio IO Biotech (IOBT)|STRO: Enterprise Value to Sales Volume|MiNK Therapeutics Inc. - Company Value to Revenue|werewolftx.com (HOWL) - Enterprise Value-to-Revenue Multiple|ALX Oncology Holdings Inc. - EV/Sales Multiple|CUE - EV/Sales Multiple|PDSB: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Sonnet BioTherapeutics Holdings Inc. (SONN)|MAIA (MAIABiotech.com) - EV/Sales Multiple|Company Value to Revenue Liminatus Pharma (LIMN)|EV/Sales Multiple LVTX|Enterprise Value-to-Revenue Coefficient NXTC|Leap Therapeutics, Inc. - Company Value to Revenue|INTS: Company Value to Revenue Ratio|Sensei Biotherapeutics Inc - EV/Sales Multiple|TOVX: Enterprise Value-to-Revenue Ratio|gritstonebio.com (GRTS) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio KA|Enterprise Value-to-Revenue Ratio NexImmune, Inc.|Company Value to Revenue Ratio TSBX (Turnstone Biologics)|Company Value to Revenue VCNX (Vaccinex, Inc.)|Enterprise Value-to-Revenue Coefficient HARP